ArticleFrontiers in medicine2026
Comparative analysis of adverse drug reaction reports for leukotriene receptor antagonists mainly indicated for allergic rhinitis and asthma: a WHO VigiAccess study.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Leukotriene receptor antagonists (LTRAs), including montelukast, pranlukast, and zafirlukast, are generally well tolerated and widely used for asthma and allergic rhinitis, but they may cause adverse drug reactions (ADRs). We compared their real-world reporting profiles to identify potential agent-specific safety differences. Methods: We conducted a descriptive and disproportionality analysis of World Health Organization (WHO) VigiAccess data retrieved on August 1, 2025. Reports were included from each drug's first year available in VigiAccess (zafirlukast, 1997; montelukast, 1998; pranlukast, 2002) through August 1, 2025. Report-level demographics were summarized using the number of individual case safety reports (ICSRs), whereas System Organ Class (SOC)- and Preferred Term (PT)-level percentages used the total number of ADR entries for the corresponding drug as the denominator. Reporting odds ratios (RORs), proportional reporting ratios (PRRs), and 95% confidence intervals (CIs) compared each target LTRA with the other two LTRAs combined. Results: We identified 37,621 ICSRs: montelukast, 33,615 (89.4%); pranlukast, 2,109 (5.6%); and zafirlukast, 1,897 (5.0%). Among 96,624 montelukast ADR entries, the SOC Psychiatric disorders accounted for Conclusions: Real-world evidence from spontaneous-report databases suggests differences in the safety-reporting profiles of montelukast, pranlukast, and zafirlukast. However, under-reporting and incomplete clinical information preclude estimation of incidence or causal inference; these findings should be interpreted as safety signals.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.